JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 650 from DKK 1,000 and keeps an Overweight rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Advances Amycretin to Phase 3 for Weight Management
- Novo Nordisk to advance subcutaneous and oral amycretin for weight management
- Novo Nordisk call volume above normal and directionally bullish
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
- Nvidia partners with Novo Nordisk to accelerate drug discovery
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue